Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study
Phase observationalN = 1,214
- Population
- Men treated with first-line cisplatin-based chemotherapy for testicular cancer, at least 1 year after treatment
- Design
- Multicentre study of men aged 55 years or younger at diagnosis who had finished first-line chemotherapy at least 1 year earlier, completed a comprehensive questionnaire and had a physical examination. Treatment data came from medical records. A cumulative burden of morbidity score counted the number and severity of adverse health outcomes; ordinal logistic regression assessed exposures; factor analysis grouped co-occurring outcomes.
- Arms
- Participants (experimental, n = 1,214): Standard first-line cisplatin-based chemotherapy (the abstract names BEP and IEP, with differing cycle numbers)
- People
- Kerns SL
Show the numbers
| Endpoint | Analysis | Participants | Control | Effect |
|---|---|---|---|---|
| Cumulative burden of morbidity categoryAll 1,214 participantsShare of participants with a low or very low cumulative burden of morbidity score | finalKerns 2018 | 47% | — | The four category percentages in the abstract (47, 30, 15 and 4.1) add up to 96.1%; the abstract does not account for the remainder. |
| Cumulative burden of morbidity categoryAll 1,214 participantsShare of participants with a medium cumulative burden of morbidity score | finalKerns 2018 | 30% | — | — |
| Cumulative burden of morbidity categoryAll 1,214 participantsShare of participants with a high cumulative burden of morbidity score | finalKerns 2018 | 15% | — | — |
| Cumulative burden of morbidity categoryAll 1,214 participantsShare of participants with a very high or severe cumulative burden of morbidity score | finalKerns 2018 | 4.1% | — | — |
| Endpoint | Analysis | Participants | Control | Effect |
|---|---|---|---|---|
| Cumulative burden of morbidity categoryAll 1,214 participantsShare of participants with a low or very low cumulative burden of morbidity score | finalKerns 2018 | 47% | — | The four category percentages in the abstract (47, 30, 15 and 4.1) add up to 96.1%; the abstract does not account for the remainder. |
| Cumulative burden of morbidity categoryAll 1,214 participantsShare of participants with a medium cumulative burden of morbidity score | finalKerns 2018 | 30% | — | — |
| Cumulative burden of morbidity categoryAll 1,214 participantsShare of participants with a high cumulative burden of morbidity score | finalKerns 2018 | 15% | — | — |
| Cumulative burden of morbidity categoryAll 1,214 participantsShare of participants with a very high or severe cumulative burden of morbidity score | finalKerns 2018 | 4.1% | — | — |